Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Checkpoint inhibitor resistance in lung cancer

Kenneth O'Byrne • 30 Jan 2020
BTOG 2020
Lung Cancer Checkpoint Inhibitors

Kenneth O’Byrne, MD, MB, BCh, BAO, Princess Alexandra Hospital & Queensland University of Technology, Woolloongabba, Australia, discusses checkpoint inhibitor resistance in lung cancer and where things may move forward in this field. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Kenneth O'Byrne

3:03
The tumor microenvironment: lung cancer
Kenneth O'Byrne • 30 Jan 2020
2:33
Concurrent immunotherapy in SCLC
Kenneth O'Byrne • 31 Jan 2020
2:28
Painting the lung cancer cell picture
Kenneth O'Byrne • 30 Jan 2020
2:34
GioTag: real world data on first-line afatinib followed by osimertinb
Kenneth O'Byrne • 25 Jan 2019

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals